Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice
November 21 2017 - 8:30AM
Novelion Therapeutics Inc. (NASDAQ:NVLN), a
biopharmaceutical company dedicated to developing new standards of
care for individuals living with rare metabolic diseases, today
announced that District Judge William Young rejected Aegerion
Pharmaceuticals’ amended criminal plea agreement which was
negotiated with the United States Department of Justice (DOJ).
Aegerion Pharmaceuticals is an indirect subsidiary of Novelion. The
Company, in consultation with its outside counsel, is currently
evaluating its options and next steps.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical
company dedicated to developing new standards of care for
individuals living with rare diseases. Novelion has a diversified
commercial portfolio through its indirect subsidiary, Aegerion
Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and
is also developing zuretinol acetate for the potential treatment of
inherited retinal disease caused by underlying mutations in RPE65
or LRAT genes. The company seeks to advance its portfolio of rare
disease therapies by investing in science and clinical
development.
CONTACT:
Amanda Murphy, Director, Investor Relations & Corporate
CommunicationsNovelion
Therapeutics857-242-5024amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024